cure patients, However, does not slowdown or

 cure or totally effective medication has yet
been created, there are a number of memory loss medications with FDA approval and
on the market at this time. These medications can only help manage the symptoms
and, in few cases, slow down the rate of progression of the disease. (alzheimers.ie)  However, these medications can be unpopular
because of their unpleasant side effects which can be particularly tough on
older people with the disease. (National institute of aging,
2017)

Current medications on the market in the United States of America:

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!


order now

 

Generic
name

Brand
name

Approved
for

Donepezil

Aricept

All stages

Galantamine

Razadyne

Mild to moderate

Revastigmine

Exelon

Mild to moderate

Memantine

Namenda

Moderate to severe

Donepezil + Memantine

Namzaric

Moderate to severe

(alz.org)

Donepezil:
Used to treat the symptoms of
Alzheimer’s by improving memory of patients, However, does not slowdown or stop
the disease in any way.

 

 

Galantamine:
This drug is used to treat Alzheimer’s
and several other nervous system diseases. This drug is isolated from plants
from the Amaryllidaceae family such
as the Caucasian snowdrop, the daffodil and the red spider lily.

 

 

 

 

 

 

Revastigmine:
Used f
the treatment of mild to moderate due to Alzheimer’s disease and Parkinson’s
disease. The drug can be administered via transdermal patch which can lessen
the intensity of the side effects. the latter form reduces the prevalence of
side effects.

 

 

 

 

Memantine:
Memantine is used to treat moderate to severe Alzheimer’s disease. It acts on the glutamatergic system by blocking NMDA receptors. This drug has also been used to treat
patients with anxiety disorders, ADHD, OCD and various other neurological
disorders.

Fig.4.)
Chemical formula:  C12H21N
 
 

 

 

 

 

 

 

 

 

 

The first three drugs on this list, Donepezil,
Galantamine and Revastigmine are all from a class of drugs which are called acetylcholinesterase
inhibitor. Cholinesterase
inhibitors are drugs that stop or impede enzymes from breaking down
acetylcholine when it is transported from one cell to another. This means that
the acetylcholine, which is in short supply in people with Alzheimer’s disease,
is not destroyed so quickly and there is more chance of it being passed on to
the next nerve cell. Cholinesterase inhibitors result in higher concentrations
of acetylcholine, leading to increased communication between nerve cells, which
in turn, may temporarily improve or stabilise the symptoms of dementia. Some
people who take cholinesterase inhibitors experience side-effects. Side-effects
from these drugs are most common when someone first administers them but,
fortunately, they often settle down with time. The most likely side effects are
diarrhoea, nausea, vomiting, muscle cramps, lowered blood pressure, insomnia,
fatigue and loss of appetite. Other reported side effects include falls and
dizziness. If the dose is increased gradually the likelihood of side effects is
lower. When prescribing these drugs, the doctor must ensure they are aware of
the patient’s medical history because they can be harmful in people with a
history of peptic ulcers, asthma, liver or kidney disease, or a very slow heart
rate.  (dementia australia, 2006)

 

 

 

 

 

 

 

 

 

 

The fourth drug on the list, Memantine, is a
different type of drug which acts
on the glutamatergic
system by
blocking NMDA
receptors.
An increased level of N-methyl-D-aspartate
(NMDA) receptor hypofunction within the brain is associated with the symptoms
of Alzheimer’s such as memory loss and psychosis. As the brain ages, the NMDA
receptors become progressively slower, contributing to decreases in memory and
learning performance. In order to inhibit this progressive
deterioration of the NMDA receptors, Memantine works by regulating the activity
of glutamate, a chemical involved in the processing of new information and the
storage of such memory. Glutamate plays an essential role in learning and
memory by triggering NMDA receptors to let a controlled amount of calcium into
a nerve cell. The calcium helps create the chemical environment required for
information storage. Excess glutamate, on the other hand, overstimulates NMDA
receptors so that they allow too much calcium into the nerve cells. That leads
to disruption and death of cells. Memantine protects cells against excess
glutamate by partially blocking MNDA receptors. (Alzheimer’s
asociation)

 

 

 

 

 

 

The last drug on the list is a combination of Donepezil and
Memantine which is commercially called Namzaric. This is subscribed in moderate
to severe cases of Alzheimer’s but can have serious side effects such as slower
heartbeat, nausea , increased production of stomach acid which can increase
risk of bleeding and stomach ulcers, and in some cases, seizures.
People taking Namzaric may see an improvement in cognition and brain function
overall, and a temporary delay in the worsening of symptoms. Unfortunately, as
with all Alzheimer’s medications on the market today, there is no evidence of
this drug stopping or curing the degenerative disease in any way. (Alzheimer’s
asociation)

Bibliography

alz.org. (n.d.). Medications
for memory loss. Retrieved from alz.org:
https://www.alz.org/alzheimers_disease_standard_prescriptions.asp
alzheimers.ie.
(n.d.). Treating dementia. Retrieved from alzheimers.ie:
https://www.alzheimer.ie/Living-with-dementia/I-have-Dementia/Treatments.aspx
dementia australia.
(2006). Drug treatments for Alzheimer’s disease. Retrieved from
https://www.dementia.org.au/files/helpsheets/Helpsheet-DementiaQandA01-CholinesteraseInhibitors_english.pdf
National
institute of aging. (2017, may 18). How is alzheimer’s disease treated.
Retrieved from nia.nih.gov:
https://www.nia.nih.gov/health/how-alzheimers-disease-treated
 

 

 

 

 

Picture references:

Fig.1) What
is Donepezil. Retrieved from http://donepezil.com/

Fig.5) What are Acetylcholinesterase inhibitors. Retrieved
from https://peaknootropics.com/using-acetylcholinesterase-inhibitors-nootropics/
Fig.6) Treatment of Alzheimer’s. Retrieved from https://www.slideshare.net/WIWomensHealth/franczak-presentation